Clinical Trials Logo

Epilepsy clinical trials

View clinical trials related to Epilepsy.

Filter by:

NCT ID: NCT03208660 Completed - Epilepsy Clinical Trials

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Start date: April 7, 2017
Phase:
Study type: Observational

This study is conducted to assess the retention rate of Fycompa when given in routine clinical care.

NCT ID: NCT03200769 Completed - Clinical trials for Sleep Apnea Syndromes

Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy

SASER
Start date: July 21, 2014
Phase: N/A
Study type: Interventional

Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy. The primary goal is to evaluate the efficacity after 3 months of obstructive sleep apnea syndrome treatment by CPAP on the epilepsy seizures frequency.

NCT ID: NCT03196271 Completed - Clinical trials for Intractable Epilepsy

Ketogenic Diet Drink Study

Start date: January 4, 2017
Phase: N/A
Study type: Interventional

An evaluation of the tolerance, compliance, acceptability and safety of a nutritionally complete liquid feed for use as part of the ketogenic diet (KD) in children 8+ years, adolescents and adults with intractable epilepsy or other disorders where the KD is indicated.

NCT ID: NCT03183076 Completed - Clinical trials for Epilepsy, Drug Resistant

Efficacy, Tolerability and Adherence of the Modified Atkins Diet on Drug-resistant Epilepsy

Start date: September 1, 2015
Phase: N/A
Study type: Interventional

The Atkins Diet Modified (ADM) is the best alternative treatment for drug-resistant epilepsy, There is a high prevalence worldwide , especially in Latin American countries, including Mexico. Low income earners, many of which do not have a social security, must meet the high costs by Antiepileptic Drugs (AEDS), which in addition should be used in conjunction or combination therapy, because monotherapy is insufficient . The diet adkins makes some changes in the traditional food habits by others that are accessible and not necessarily expensive, whose mechanism allows for better control of the seizures.

NCT ID: NCT03179891 Completed - Epilepsy Clinical Trials

Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy

Start date: May 25, 2017
Phase: Phase 2
Study type: Interventional

This Phase 2 open-label, two-way study was conducted in adult subjects with epilepsy who were on stable regimens of anti-epileptic drugs (AEDs) and who were admitted to an Epilepsy Monitoring Unit (EMU), General Clinical Research Center (GCRC), or similar facility for evaluation of their seizures. All subjects received a single DBF 12.5 mg dose during the Interictal State and a single DBF 12.5 mg dose during the Ictal/peri-ictal state with at least 14 days washout between the 2 doses.

NCT ID: NCT03166215 Completed - Clinical trials for Developmental and/or Epileptic Encephalopathies

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

Start date: August 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to characterize the multiple-dose safety and tolerability profile of TAK-935 in adult participants with developmental and/or epileptic encephalopathies.

NCT ID: NCT03123302 Completed - Clinical trials for Intracranial Aneurysm

Our Anesthesia Experience During MRI Scan

Start date: February 1, 2017
Phase:
Study type: Observational

In this study we aim to investigate the relationship between our anesthesia practice and post procedure complications after MRI scanning with sedation. This is a retrospective, single center observational study. All patients undergoing MRI scan during the study period will be included.

NCT ID: NCT03116828 Completed - Clinical trials for Epilepsy With Partial On-set Seizures

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Start date: July 7, 2017
Phase: Phase 4
Study type: Interventional

A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures

NCT ID: NCT03116321 Completed - Epilepsy Clinical Trials

Bioequivalence of Two Different Sources of Eslicarbazepine Acetate

Start date: December 3, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether the test product, eslicarbazepine acetate 800 mg tablets (test 1, To be marketed (TBM) Treatment A), and the reference product, eslicarbazepine acetate 800 mg tablets (current Active pharmaceutical ingredient (API) source - Marketed formulation (MF)) (Reference, Treatment C), are bioequivalent and to demonstrate dose equivalence between eslicarbazepine acetate 4 x 200 mg tablets (test 2, TBM Treatment B) and eslicarbazepine acetate 800 mg tablet (Reference).

NCT ID: NCT03106727 Completed - Hypertension Clinical Trials

Evaluating the Impact of a Community Health Worker Program in Neno, Malawi

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

This protocol concerns the implementation and evaluation of an intervention designed to realign the existing cadre of Community Health Workers (CHW) in Neno District, Malawi to better support the care needs of the clients they serve. The proposed intervention is a 'Household Model' where CHWs will be assigned to households, rather than HIV or TB specific patients, and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes, and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program. Eleven sites (health centres and hospitals) were arranged into six clusters by estimated size of the catchment area populations, with a population range of 11,680 to 26,260 and an average population of 20,400. The order in which the intervention will be rolled out across the sites will be randomized so that the intervention can be evaluated in a stepped-wedge cluster randomized controlled trial. These clusters were grouped based mostly on geographic location but also on catchment area sizes, in order to maximize feasibility of training for the CHW team and not overload CHW training sessions with too many trainees.